During the past decade, New Hampshire Oncology Hematology PA-Concord conducted 74 clinical trials. In the 10-year time frame, 74 clinical trials started and 86 clinical trials were completed, i.e. on average, 116.2% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 42 clinical trials were completed. i.e. 127.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New Hampshire Oncology Hematology PA-Concord" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 60 trials, followed by "National Cancer Institute (NCI)" with 44 trials sponsored, "SWOG Cancer Research Network" with 27 trials sponsored, "Alliance Foundation Trials, LLC." with 6 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 6 trials sponsored. Other sponsors include 38 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New Hampshire Oncology Hematology PA-Concord" #1 collaborator was "National Cancer Institute (NCI)" with 115 trials as a collaborator, "SWOG Cancer Research Network" with 12 trials as a collaborator, "Cancer and Leukemia Group B" with 10 trials as a collaborator, "NCIC Clinical Trials Group" with 10 trials as a collaborator and "Eastern Cooperative Oncology Group" with 7 trials as a collaborator. Other collaborators include 122 different institutions and companies that were collaborators in the rest 91 trials.

According to Clinical.Site data, the most researched conditions in "New Hampshire Oncology Hematology PA-Concord" are "Breast Cancer" (27 trials), "Lung Cancer" (11 trials), "Colorectal Cancer" (10 trials), "Prostate Cancer" (10 trials) and "Lymphoma" (9 trials). Many other conditions were trialed in "New Hampshire Oncology Hematology PA-Concord" in a lesser frequency.

Most popular intervention types in "New Hampshire Oncology Hematology PA-Concord" are "Drug" (158 trials), "Other" (94 trials), "Biological" (58 trials), "Procedure" (27 trials) and "Radiation" (22 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (40 trials), "Quality-of-Life Assessment" (33 trials), "Questionnaire Administration" (21 trials), "Paclitaxel" (18 trials) and "placebo" (17 trials). Other intervention names were less common.

The vast majority of trials in "New Hampshire Oncology Hematology PA-Concord" are 135 trials for "All" genders, 30 trials for "Female" genders and 21 trials for "Male" genders.

Currently, there are NaN active trials in "New Hampshire Oncology Hematology PA-Concord". undefined are not yet recruiting, 30 are recruiting, 58 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 85 completed trials in New Hampshire Oncology Hematology PA-Concord, 1 suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in New Hampshire Oncology Hematology PA-Concord, 3 "Phase 1" clinical trials were conducted, 67 "Phase 2" clinical trials and 112 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".